兆科眼科-B(06622.HK)香港公開發售獲56倍認購 上限定價16.8港元/股
格隆匯 4 月 28日丨兆科眼科-B(06622.HK)發佈公吿,公司全球發售約1.236億股股份,其中香港發售股份4942.7萬股,國際發售股份7414.05萬股,另有15%超額配股權;發售價釐定為每股股份16.80港元,每手買賣單位500股;高盛及Jefferies為聯席保薦人,預期股份將於2021年4月29日於聯交所主板掛牌上市。
根據國際發售初步提呈發售的發售股份已獲超額認購,相當於國際發售項下初步可供認購的股份總數的約5.3倍以上。根據香港公開發售提呈發售的發售股份接獲大量超額認購。已合共接獲111,183份有效申請,認購合共6.99億股香港發售股份,相當於香港公開發售項下初步可供認購股份總數的約56倍。
按發售價每股股份16.80港元,以及根據與基石投資者訂立的基石投資協議,基石投資者已認購2546.1萬股發售股份,相當於公司緊隨全球發售完成後已發行股份總數約4.76%及全球發售項下發售股份數目的約20.60%,在各情況下均假設超額配股權未獲行使。
根據發售價每股股份16.80港元,公司自全球發售收取的所得款項淨額估計約為19.416億港元。公司擬將該等所得款項淨額約32.0%用於核心產品的臨牀開發及商業化;約46.0%為集團的其他在研候選藥物的持續研發活動及商業化提供資金;約7.0%為位於南沙的生產設施進行生產線擴張,以籌備未來年度的產品上市;約5.0%為集團的業務開發活動及在研藥物的擴展提供資金;及10.0%用於營運資金及其他一般企業用途。倘超額配股權獲悉數行使,按發售價每股股份16.80港元計算,公司將就將予配發及發行的1853.5萬股額外股份收取額外所得款項淨額約2.974億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.